Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05590728 · ClinicalTrials.gov registry record · Phase 1
Safety of Intravenous Apramycin in Adults
A Phase 1 study of Bacterial Infection, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
- 1
- Study location
NCT05590728 is a Phase 1 study of Bacterial Infection that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 16 participants, below the 103-participant average among 8 other Bacterial Infection trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05590728, a Phase 1 study of Bacterial Infection, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
- 1
- Study location
Study Summary
A Phase I, open label study of a single dose of 30 mg/kg of apramycin administered intravenously (IV) over 30 (+/- 5) minutes. Twenty subjects will be enrolled in the study to one of 5 cohorts, T1-T5, each corresponding to a timepoint after initiation of infusion at which a single fiberoptic bronchoscopy with bronchoalveolar lavage (BAL) is performed. There will be 4 subjects per cohort. Cohort T5 will be enrolled after plasma and lung apramycin concentrations and preliminary PK data analysis are completed in cohorts T1-T4. Enrollment and dosing will be determined by bronchoscopy schedule. For each cohort, if 2 subjects are scheduled to receive study drug on the same day, the dose will be administered sequentially at least 2 hours apart. The primary objective is to assess plasma pharmacokinetic (PK) profile of apramycin and lung penetration of apramycin in epithelial lining fluid (ELF) and alveolar macrophages (AM) after single intravenous (IV) apramycin dose of 30 mg/kg in healthy subjects.
Conditions Studied
Interventions
- DRUG Apramycin (EBL-1003)
Study Locations (1)
Tennessee
- Alliance for Multispecialty Research, LLC - Knoxville - Knoxville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2023-06-16 |
| Est. Completion | 2023-10-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05590728
The ClinicalTrials.gov registry entry for NCT05590728 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 103-participant average among 8 other Bacterial Infection trials with a reported enrollment target (84% lower). The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Bacterial Infection appearing as the primary indexed condition, and to 1 intervention - of which Apramycin (EBL-1003) is the first listed.
NCT05590728 reports 1 study location spanning 1 distinct geographic area - top geographies include Tennessee.
Frequently Asked Questions
What is clinical trial NCT05590728 about?
NCT05590728 is a clinical study titled "Safety of Intravenous Apramycin in Adults". A Phase I, open label study of a single dose of 30 mg/kg of apramycin administered intravenously (IV) over 30 (+/- 5) minutes. Twenty subjects will be enrolled in the study to one of 5 cohorts, T1-T5, each corresponding to a timepoint after initiation of infusion at which a single fiberoptic broncho...
What is the current status of trial NCT05590728?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2023-06-16. Estimated completion is 2023-10-22.
What conditions does trial NCT05590728 study?
This clinical trial studies the following conditions: Bacterial Infection.
What interventions are being tested in trial NCT05590728?
The interventions under investigation include: Apramycin (EBL-1003) (DRUG).
Who is sponsoring clinical trial NCT05590728?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05590728 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bacterial Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Trial to Evaluate the Pharmacokinetics and Safety of AVYCAZ(R) in Combination With Aztreonam
COMPLETED · Phase 1
-
Optimization of Beta-lactam Dosing in Critically Ill Patients With Cystatin C (OPTIMIZE-GNI)
RECRUITING · Phase 4
-
Rifaximin 200 mg Plus Oral Rehydration vs Oral Rehydration Alone in Children With Acute Diarrhea
RECRUITING · Phase 4
-
Efficacy and Safety Study of Brilacidin to Treat Serious Skin Infections
COMPLETED · Phase 2
-
Larval Debridement Therapy Versus Sharp Debridement to Remove Biofilm
COMPLETED · NA
-
Efficacy and Safety of Ceftaroline Versus Linezolid in Subjects With Complicated Skin and Skin Structure Infections
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.